Soc. Generale Knock-Out TransDigm.../ DE000SQ3FFQ7 /
31/05/2024 21:51:29 | Diferencia+0.210 | Bid21:59:49 | Ask21:59:49 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
6.790EUR | +3.19% | 6.840 Volumen de oferta: 3,000 |
6.890 Tamaño/ Volumen/ Formato de Ask: 3,000 |
Transdigm Group Inco... | 604.4387 USD | 31/12/2078 | Call |
GlobeNewswire
1:00
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-li...
GlobeNewswire
02/06
Allergic diseases directly cost between 1,800 and 6,600 euros per patient per year
GlobeNewswire
02/06
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 202...
GlobeNewswire
02/06
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página